Zavesca

Active Ingredient(s): Miglustat
FDA Approved: * July 31, 2003
Pharm Company: * ACTELION PHARMS
Category: Enzymes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zavesca Overview

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I Gaucher disease (GD1). It is marketed under the trade name Zavesca. Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Mechanism of action 5 Chemistry 6 Research 7 See also 8 References Medical uses Miglustat is used to treat adults with mild-to-moderate type I Gaucher disease for whom enzyme replacement therapy is un...

Read more Zavesca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Miglustat

Recent Zavesca Forums:

zavesca
1 Reply RSS
Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nausea, back pain, constipation and weight loss. You can read more here: Do you have any other questions?
Updated 8 years ago.
Sun, Aug 23 '09, 2:54 PM

Possible Dosages for this and Related Drugs:

Miglustat

Capsule: 100mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zavesca: (1 result)

Sorted by National Drug Code

66215-201 Zavesca 100 mg Oral Capsule by Actelion Pharmaceuticals Us, Inc.

Other drugs which contain Miglustat or a similar ingredient: (1 result)

Miglustat

Possibly related Zavesca Topics:

zavesca Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nause... 1 reply